Date: 2015-07-24
Type of information: Joint-venture agreement
Compound: FKB238
Company: AstraZeneca (UK) Fujifilm Kyowa Kirin Biologics (Japan)
Therapeutic area: Cancer - Oncology
Type agreement: joint-venture
Action mechanism: monoclonal antibody/biosimilar. FKB238 is a biosimilar version of bevacizumab, an anti-VEGF1 humanized monoclonal antibody with established efficacy across a range of cancers including colorectal and non-small cell lung cancer.
Disease: solid tumors
Details: * On July 24, 2015, Fujifilm Kyowa Kirin Biologics announced that it has entered into an agreement with AstraZeneca to establish a 50/50 joint venture for the development and commercialisation of FKB238 in development for the treatment of multiple solid tumours. FKB238 is a biosimilar version of bevacizumab. Fujifilm Kyowa Kirin Biologics commenced its Phase I clinical trial for FKB238 in Europe in November 2014.
Under the terms of the agreement, the new joint venture that is equally co-funded by the two companies and will use FKB238’s non-clinical, clinical development data compiled by Fujifilm Kyowa Kirin Biologics thus far. Fujifilm Kyowa Kirin Biologics will transfer the rights to FKB238 to the new joint venture, and will receive a lump-sum payment of $ 45 million in return.
Financial terms:
Latest news:
